规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
靶点 |
IRE1α endoribonuclease
|
---|---|
体外研究 (In Vitro) |
MKC-3946 causes mild growth inhibition in MM cell lines while having no harmful effects on healthy mononuclear cells. Crucially, it amplifies the cytotoxicity caused by 17-AAG or bortezomib considerably, even when external IL-6 or bone marrow stromal cells are present. XBP1s is induced by both 17-AAG and bortezomib, indicating ER stress, which is inhibited by MKC-3946. MKC-3946 increases the apoptosis brought on by these agents and is linked to an increase in CHOP. Treatment with MKC-3946 does not impede the function of IRE1α kinase or the binding of activated IRE1α to TRAF2 and subsequent JNK signaling[1].
|
体内研究 (In Vivo) |
MKC-3946 significantly inhibits the growth of MM cells in a model of in vivo ER stress by inhibiting XBP1 splicing[1].
|
细胞实验 |
For three hours, RPMI 8226 cells are either treated with or without Tm (5 μg/mL) in addition to MKC-3946 (0-10μM). After extracting total RNA, XBP1 and β-actin mRNA are assessed via RT-PCR.
|
动物实验 |
CB17 SCID mice (48-54 days old) are treated for 21 days beginning on day 1 after receiving a subcutaneous injection of 1×107 RPMI 8226 cells mixed with Matrigel on day 0. Four groups (n=8) of mice are allocated to receive daily intraperitoneal injections of 100 mg/kg MKC-3946; twice-weekly intravenous injections of 0.15 mg/kg bortezomib; a combination of intraperitoneal injections of MKC-3946 and intravenous injections of bortezomib; and intraperitoneal injections of 10% HPBCD with normal saline as a vehicle control. Mice are euthanized when tumors grow to a length of 1.5 cm. Tumor volume is estimated from caliper measurements every 3–4 days. From the moment of treatment initiation until death, survival is assessed.
|
参考文献 |
分子式 |
C21H20N2O3S
|
|
---|---|---|
分子量 |
380.46
|
|
精确质量 |
380.12
|
|
元素分析 |
C, 66.30; H, 5.30; N, 7.36; O, 12.62; S, 8.43
|
|
CAS号 |
1093119-54-0
|
|
相关CAS号 |
|
|
外观&性状 |
Solid powder
|
|
SMILES |
CN1CCN(CC1)C(=O)C2=CC=C(S2)C3=CC4=C(C=C3)C(=C(C=C4)O)C=O
|
|
InChi Key |
IVQVBMWPWPTSNO-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C21H20N2O3S/c1-22-8-10-23(11-9-22)21(26)20-7-6-19(27-20)15-2-4-16-14(12-15)3-5-18(25)17(16)13-24/h2-7,12-13,25H,8-11H2,1H3
|
|
化学名 |
2-hydroxy-6-[5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl]naphthalene-1-carbaldehyde
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2 mg/mL (5.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6284 mL | 13.1420 mL | 26.2840 mL | |
5 mM | 0.5257 mL | 2.6284 mL | 5.2568 mL | |
10 mM | 0.2628 mL | 1.3142 mL | 2.6284 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
MKC-3946 is an IRE1α endoribonuclease inhibitor, which triggers modest cytotoxicity in MM cells.Blood.2012 Jun 14;119(24):5772-81. th> |
---|
MKC-3946 blocks XBP1 splicing and enhances cytotoxicity induced by bortezomib or 17-AAG.Blood.2012 Jun 14;119(24):5772-81. td> |
MKC-3946 enhances ER stress-mediated apoptosis induced by bortezomib or 17-AAG.Blood.2012 Jun 14;119(24):5772-81. td> |